Newly synthesized benzoxazinorifamycin, KRM-1648, was studied for its in vivo anti-Mycobacterium avium complex (MAC) activities. When the MICs were determined by the agar dilution method with Middlebrook 7H11 agar medium, KRM-1648 exhibited similarly potent in vitro antimicrobial activities against the MAC isolated from AIDS and non-AIDS patients, indicating possible usefulness of KRM-1648 against AIDSassociated MAC infections. KRM-1648 exhibited potent therapeutic activity against experimental murine infections induced by M. intracellulare N-260 (virulent strain) and N-478, which has much weaker virulence. Similarly, KRM-1648 exhibited an excellent therapeutic efficacy against M. intracelulare infection induced in NK-cell-deficient beige mice (as a plausible model for AIDS-associated MAC infection), in which a much more progressed state of gross lesions and bacterial loads at the sites of infection were observed. When the infected beige mice were killed at weeks 4 and 8, obvious therapeutic efficacy was seen on the basis of reduction in the incidence and degree of lung lesions and bacterial loads in the lungs and spleen with infections due to M. intracelulare N-241, N-256, and N-260. In this case, the efficacy was the highest in N-260 infection, followed by strain N-241. When mice were observed until infection-induced death, survival time of the infected beige mice was found to be prolonged by KRM treatment. However, KRM-1648 was not efficacious in suppressing the progression of pulmonary lesions and the increase in bacterial loads at the sites of infection, including lungs and spleen, at the late phase of infection. This may imply some difficulty with chemotherapy for AIDSassociated MAC infection, even with KRM-1648 treatment, which has excellent in vitro and in vivo anti-MAC activities, as shown in the present study.
(RBT), rifapentine, and so on, are highly active against slowly growing mycobacteria, particularly Mycobacterium tuberculosis and some nontuberculous mycobacteria (1, 3, 5, 7, 14, 18, 24, 28, 29, 36) . However, they are not so excellent in their in vitro activity against M. avium complex (MAC) (5, 19, 28) , supposedly because of the permeability barrier of the organisms (11, 25) . Moreover, it is not known whether RMP and other rifamycins are really efficacious in the treatment of patients with MAC infections. Some investigators have reported that multidrug chemotherapy, including treatment with RMP, has been used in many cases of clinical management of AIDS-or non-AIDS-associated MAC patients with success (4, 6) . In contrast, others have reported unavoidable difficulty in clinical control of MAC, even by using RMP combined with other drugs (36) . For instance, Rosenzweig (27) reported that sustained conversion of sputum with such chemotherapy alone was achieved in only 41% of patients and, after a 6-month trial of drugs including RMP, 33% of the patients experienced relapse.
Because MAC infections are rapidly increasing in immunocompromised hosts, especially in AIDS patients (38) , new rifamycin derivatives having strong anti-MAC activity are desired. In relation, it is noteworthy that a substantial proportion of M. avium strains are considerably susceptible to RMP and RBT (5, 18) , and there is a synergistic effect of these rifamycins with ethambutol (16, 17) . Such a new * Corresponding author.
rifamycin with a high in vitro anti-MAC activity and superior pharmacokinetics may be able to exhibit an excellent therapeutic efficacy against the MAC infections, when used in combination with other drugs, especially ethambutol. In a recent study (31) , we found that newly synthesized rifamycin derivatives, benzoxazinorifamycins (KRMs), with chemical structures of 3'-hydroxy-5'-(4-alkylpiperazinyl)-benzoxazinorifamycins (alkyl residues: isobutyl, propyl, sec-butyl, sec-butyl [R configuration], and sec-butyl [S configuration] for KRM-1648, -1657, -1668, -1686, and -1687, respectively), exhibited markedly stronger in vitro antimycobacterial activities, especially against the MAC. Their MICs for 50 and 90% of the strains against the MAC were about 64 times smaller than those of RMP. Moreover, KRMs, especially KRM-1648, exhibited higher antimicrobial activity against the MAC phagocytosed in macrophages than did RMP and RBT. Similar results were reported by Yamamoto et al. (37) . In this study, KRM-1648 was studied for its in vivo activity against MAC infections induced in mice. to give an optical density of 0.1 at 540 nm (approximately 107 CFU/ml) as measured by a spectrophotometer (Model 100-10; Hitachi Co. Ltd., Hitachi, Japan). The bacterial suspension was then diluted 10 times in the saline to prepare an inoculum. MIC was determined by the agar dilution method as previously described (35) . Briefly, the inoculum (5 pAl) was spotted on 7H11 agar plates containing 100 -0.0125-,ug/ml doses (twofold dilution) of drugs. The MICs of the drugs were determined 14 
RESULTS
In vitro activity of KRM-1648 against the MAC isolated from AIDS and non-AIDS patients. In our previous study, in vitro activity of KRM-1648 against MAC was examined by using only the strains isolated from non-AIDS patients. Therefore, it is unclear whether KRM-1648 is similarly active against MAC strains from AIDS patients and those from non-AIDS patients. Here, we determined the MICs of KRM-1648, RMP, and RBT against the MAC strains isolated from AIDS (M. avium, 77 strains; M. intracellulare, 11 strains) and non-AIDS (M. avium, 62 strains; M. intracellulare, 49 strains) patients. KRM-1648 was similarly efficacious against the MAC strains isolated from both AIDS and non-AIDS patients, and its MIC for 90% of strains tested (0.05 to 0.1 j,g/ml) was much smaller than those of RMP (3.13 to 25 ,ug/ml) and RBT (0.4 to 1.6 jig/ml).
Therapeutic efficacy of KRM-1648 and other KRMs against the murine infections with M. intracellulare N-260 induced in BALB/c and beige mice. Table 1 shows the therapeutic activities of various KRMs against infection with M. intracellulare N-260 induced in BALB/c mice (experiment 1) and the efficacy of KRM-1648 against the N-260 infection induced in beige mice (experiment 2). Firstly, in experiment 1, when infected mice were given each of the five KRMs at doses of 0.2 and 0.4 mg per mouse, the incidence of gross lung lesions was completely inhibited, accompanied by a 1.9-to 3.1-log decrease in the number of CFUs of the organisms in the lungs at week 8 compared with those for untreated animals, although such a marked reduction in the number of CFUs was not observed for the spleen. Moreover, infectioninduced splenomegaly (2.4-fold increase in spleen weight at week 8 for untreated mice) was also markedly suppressed; there was 70 to 85% reduction by the five KRMs at the dose of 0.4 mg per mouse compared with that for untreated control mice infected with M. intracellulare. In this experiment, KRM-1648, followed by KRM-1668, was most efficacious in controlling M. intracellulare infection in terms of inhibiting the increase in the number of CFUs in the lungs.
It has been reported that NK-cell-deficient beige mice are much more susceptible to MAC infection (8, 9) . As indicated in Table 1 (experiment 2) , when the beige mice were infected with M. intracellulare N-260, much faster bacterial growth in the lungs and spleen was seen compared with those for BALB/c (experiment 1) and C57BL/6 (30) mice with a normal genotype (+/+). In this experiment, when KRM-1648 was given at a dose of either 0.2 or 0.4 mg per mouse and the animals were killed at weeks 4 and 8, the agent efficiently reduced the incidence or degree of lung lesions or both and the growth of the organisms in the visceral organs. However, it was noted that KRM-1648 was unable to eliminate the organisms at the sites of infection, even when given at a dose of 0.4 mg per mouse, in the present administration protocol. Although a transient decrease in the number of CFUs in the spleen as well as lungs compared with the number of CFUs on day 1 was observed for mice given KRM-1648 at a dose of 0.4 mg per mouse in the relatively early phase of infection, such as at week 4, an increase in the number of organisms was seen at week 8, despite continuous KRM treatment. A similar tendency was also reported by 388 TOMIOKA ET AL. Kuze et al. (23) in murine experimental infection induced by another MAC strain, M. intracellulare 31F093T. Table 2 compares the in vivo activity of KRM-1648 against MAC infection induced in beige mice with those of RMP and RBT. KRM completely inhibited the incidence of gross pulmonary lesions in MAC-infected beige mice at week 6 and caused a much lower degree of lung lesions at week 12 compared with those in untreated mice. Its efficacy to suppress the progression of lung lesions was much more obvious than those of RBT and RMP. MAC infectioninduced splenomegaly (11-fold increase in spleen weight for untreated mice) was also suppressed by treatment with these rifamycins. KRM-1648, RMP, and RBT caused, respectively, 93, 44, and 51% inhibition of the splenomegaly seen with untreated animals at week 12. KRM-1648 markedly suppressed the bacterial growth in the lungs and spleens of beige mice, and about 2-and 3-log reductions were seen at weeks 6 and 12, respectively, compared with those of untreated control mice. Moreover, the degree of lung lesions in mice given KRM was markedly lower than the degrees seen with animals given RMP or RBT. A statistically significant difference in the number of CFUs in the lungs and spleens for mice given KRM and those given either RMP or RBT was observed (P < 0.05, Student's t test). Thus, the therapeutic efficacy of KRM is thought to be much greater than those of RMP and RBT.
Therapeutic activity of KRM-1648 against the murine infections with M. intracellulare N-478 induced in BALB/c mice. As shown in Table 3 (Table 4 ), M. intracellulare N-256 (experiment 1) and N-241 (experiment 2), which have the same in vitro susceptibility to KRM-1648 (MIC, 0.05 p.g/ml), a comparable but somewhat weaker efficacy was observed compared with that of M. intracellulare N-260 infection, based on the incidence of pulmonary lesions and the number of CFUs of organisms recovered from the lungs and spleen at weeks 4 and 8. Table 5 shows the survival time, the degree of lung lesions, and the number of CFUs in the lungs and spleens at the deaths of individual animals due to N-256 infection. The mean survival time of infected animals was prolonged from 9.40 ± 0.08 and 9.40 ± 0.08 for mice 1 to 5, 9.11 + 0.06 and 9.18 ± 0.09 for mice 6 to 10, and 10.41 ± 0.05 and 10.00 ± 0.19 for mice 11 to 16. 74 to 137 days by KRM treatment at a dose of 0.4 mg per mouse, although KRM given at a dose of 0.2 mg per mouse failed to exhibit such an effect. Despite the fact that KRM given at a dose of 0.4 mg per mouse was able to prolong the survival time of infected beige mice, bacterial loads in the lungs and spleens of dead mice were larger for mice given KRM at this dose, compared with those for untreated control dead mice. However, it should be emphasized that KRM treatment was significantly efficacious in retarding the growth of the organisms in the visceral organs in the earlyto-middle phase of infection (Table 4) .
A similar situation was seen with infection due to strain Table 1 , footnote b. cThe mean values for five mice are given. The average standard error of the mean was 0.14 and did not exceed 0.24 for experiment 1 and was 0.14 and did not exceed 0.24 for experiment 2. At day 1, the values (log CFU) for lungs and spleen, respectively, were 4.81 and 6.48 (experiment 1) and 5.01 and 6.39 (experiment 2). N-241, as shown in Table 6 . In this case, the prolongation of survival time by KRM treatment at a dose of 0.2 mg per mouse was more marked than that seen with N-256 infection, whereas the efficacy seen with mice given KRM at a dose of 0.4 mg per mouse was not as obvious as was seen with N-256 infection (Table 6 versus Table 5 ). In this case, the number of CFUs in the lungs and spleen at the death of the animals was also larger for mice given KRM-1648 at a dose of 0.4 mg per mouse than for untreated mice. Pharmacokinetics of KRM-1648. Table 7 compares the distribution of KRM-1648 in tissue with those of RMP and 
DISCUSSION
In this study, we found the following. First, KRM-1648 had a potent in vitro antimicrobial activity against MAC strains isolated from both AIDS and non-AIDS patients.
There was no marked difference in the values against AIDS isolates and those against non-AIDS isolates. This is inconsistent with the finding by Horsburgh et al. (20) that there was a significant difference in MAC susceptibility to some antimicrobial agents, including RMP, with AIDS and non-AIDS isolates. They reported that the ratio of RMP (10 ,ug/ml)-susceptible strains in 75 non-AIDS isolates was 67%, which was significantly (P < 0.001) larger than the value (27%) for AIDS isolates (57 strains). The reason for this inconsistency is thought to be because they tested the drug susceptibility of all MAC isolates, without classifying them as M. avium or M. intracellulare. We found that the drug susceptibilities of the two species differed considerably from each other, in particular with RMP and new quinolones (32, 35) . Moreover, the ratio of M. avium and M. intracellulare in AIDS isolates is markedly different from that in non-AIDS isolates (13, 20) . For instance, Guthertz et al. (13) reported that 98% of the strains isolated from 44 patients with AIDS were identified as M. avium by Gen-Probe testing, while 40% of MAC isolates recovered from 109 patients without AIDS were M. intracellulare. These findings might be responsible for a certain degree of difference in the drug susceptibilities of MAC isolates from AIDS and non-AIDS patients, as they have observed.
Secondly, this study revealed the superiority of the therapeutic efficacy of KRM-1648 against M. intracellulare infections induced in mice, in terms of suppression of splenomegaly, the incidence or degree of gross pulmonary lesions or both, and bacterial growth in the lungs and spleen. The pharmacokinetics of KRM-1648 was comparable to that of RMP and somewhat better than that of RBT (Table 7) . Therefore, the excellent therapeutic efficacy of KRM-1648 against MAC infection seems to be due to its strong in vitro anti-MAC activity (31, 37) .
Thirdly, KRM-1648 exhibited therapeutic efficacy against N-260 strain infection induced in NK-cell-deficient beige mice (as a plausible model for AIDS-associated MAC infection) similar to that of a normal genotypic strain of mice. However, it is noted that in vivo activity of KRM-1648 in beige mice infected with M. intracellulare N-256 or N-241 was somewhat inferior to that seen with M. intracellulare N-260 infection, although it has the same MIC (0.05 ,ug/ml) against these three M. intracellulare strains. Although the precise reason for this is unclear, the following may be stated. First, a possible difference in the virulence of these M. intracellulare strains to mice does not seem to cause this phenomenon, because these three strains (N-260, N-256, and N-241) had similar levels of virulence to mice, showing comparable growth at the sites of infection (lungs and spleens) around weeks 8 to 12. Second, there may be more strict dependency of host defense mechanisms upon NK-cell VOL. 36, 1992 functions with infections due to M. intracellulare strains, such as N-241 and N-256, compared with strain N-260 infection. In other words, KRM may require intact NK-cell functions to fully exhibit its in vivo antimicrobial activity, with N-241 or N-256 infection. Indeed, the possibility has been proposed that NK cells play some important role in host defense mechanisms not only in virus infections but also in other microbial infections (10, 15, 19) .
In relation to this, it is noteworthy that beige mice have an impaired cytotoxic T-cell activity in addition to NK-cell deficiency (2, 33) . Therefore, it is also possible that KRM may need intact-cell functions of CD8+ T cells to efficiently express its in vivo activity against M. intracellulare infection. Indeed, CD8+ T cells have been proposed to play some important role in host resistance to mycobacterial infections (21) , although CD4+ T cells mainly mediate the host immune response to mycobacterial infections (22) . While NK cells are known to contribute to host resistance in the early phase of microbial infections (34), CD8+ T cells are generated in a relatively late phase of chronic infections, including mycobacterial infections (21) . This may be a possible explanation for our finding that KRM-1648 failed to suppress the bacterial growth at the sites of infection in the progressed state of test M. intracellulare (N-241, N-256, and N-260)-induced infections, despite the fact that the agent showed an appreciable activity to inhibit bacterial growth in the early phase of infection. This can be easily explained if we assume that in MAC infections, CD8+ T cells rather than NK cells play an important role in the expression of host resistance. In any case, these situations may imply some difficulties with clinical treatment of AIDS-associated MAC infections even with KRMs, although they possess a superior in vitro activity against MAC strains isolated from both AIDS and non-AIDS patients and excellent in vivo anti-M. intracellulare activity in experimental infections in normal genotypic mice.
In any case, KRM-1648 has an excellent in vivo activity against M. intracellulare infection induced in mice. Since rifamycins are known to exhibit synergistic in vitro activities against the MAC with other antimicrobial agents, especially ethambutol (16, 17) , it is possible to improve the in vivo activity of KRM-1648 by combined use with other antimicrobial agents. On this point, further studies are under way.
